Owen A. O’Connor, Chief Scientific Officer at TG Therapeutics, discusses umbralisib, which was approved for the treatment of relapsed or refractory follicular lymphoma (FL) and relapsed or refractory marginal zone lymphoma (MZL).
In the first part of the interview, Dr. O’Connor discussed the method of action of umbralisib, the first and only, oral, once daily, inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon to be approved by the U.S. Food and Drug Administration (FDA). As Dr. O’Connor explains, PI3K-delta is known to play an important role in supporting cell proliferation and survival, cell differentiation, intercellular trafficking and immunity and is expressed in both normal and malignant B-cells. CK1-epsilon is a regulator of oncoprotein translation and has been implicated in the pathogenesis of cancer cells, including lymphoid malignancies.
In the second part of the interview, Dr. O’Connor describes the phase 2 UNITY-NHL study, the results of which led to the FDA’s approval of umbralisib. The study involved 117 patients with FL who received at least 2 prior systemic therapies and 69 patients with MZL who received at least 1 prior therapy. The primary endpoint of the study was an independent review committee (IRC) assessed overall response rate (ORR) which was 43% in the FL cohort and 49% for the MZL cohort. Serious adverse reactions occurred in 18% of patients who received umbralisib.
To learn more about these lymphomas and other rare cancers, visit https://checkrare.com/diseases/cancers/